Clinical Trials Logo

High Risk clinical trials

View clinical trials related to High Risk.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04614363 Completed - Prostate Cancer Clinical Trials

68 Ga-PSMA for High Risk Prostate Cancer

Start date: October 13, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective, single-center, open-label pilot study of 68GA-PSMA-11 given at a single time prior to PET/CT imaging in men with localized high risk prostate cancer or biochemical recurrence. The imaging agent (68 Ga-PSMA 11 will be administered on an outpatient basis. It will be administered prior to the PET/CT imaging. The objective is to evaluate the distribution of 68GA-PSMA-11 in tissues and to determine if this alters the planned clinical management.

NCT ID: NCT04548102 Completed - Pregnancy Clinical Trials

Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman

Start date: September 30, 2019
Phase: N/A
Study type: Interventional

Up till now, there is insufficient evidence that daily fetal movement counting for pregnant women who are already have a history of high risk pregnancy is beneficial or not in term of early detection and preventing adverse pregnancy outcomes. Aim The aim of the current study is to evaluate the effect of fetal movement counting on maternal and fetal outcome

NCT ID: NCT04298619 Completed - Hodgkin Lymphoma Clinical Trials

Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission

HOLYFU
Start date: June 2001
Phase:
Study type: Observational

Cohort study enrolled high-risk Hodgkin Lymphoma patients in first relapse after induction therapy followed after remission either with a systemic imaging-based surveillance (Imaging cohort) or with standard clinical-based surveillance (standard cohort).

NCT ID: NCT01030861 Completed - Clinical trials for Impaired Glucose Tolerance

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

Start date: August 2010
Phase: Phase 2
Study type: Interventional

The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease. Teplizumab has been studied in new onset type 1 diabetes for testing of efficacy and safety in previous studies; other studies are currently in progress. The results of previous studies indicate that teplizumab reduces the loss of insulin production during the first year after diagnosis in individuals with type 1 diabetes. The purpose of this study is to determine if teplizumab can interdict the immune process that causes the destruction of insulin secreting beta cells in the pancreas during the "pre-diabetic" state and thereby prevent or delay the onset of type 1 diabetes.

NCT ID: NCT00590785 Completed - Breast Cancer Clinical Trials

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

Start date: August 13, 1996
Phase: Phase 3
Study type: Interventional

To compare disease-free survival (DFS), overall survival (s), and toxicity of high-isk primary breast cancer patients with negative axillary lymph nodes or with one to three positive nodes treated with adjuvant high-dose chemotherapy with doxorubicin plus cyclophosphamide (AC), versus high-dose sequential chemotherapy with doxorubicin followed by cyclophosphamide (A-->C).